

# Therapeutics are key to the COVID-19 response, and high potential small molecule options are coming



A rapidly **evolving and unpredictable pandemic** with emerging variants



Challenges in the **roll out and uptake of vaccines** with only 2% coverage in LICs [target 20% by end of 2021], and continued transmission amongst the vaccinated



An estimated **~140M cases in LMIC countries** in the next 12 months<sup>1</sup>



A need to **save lives now & speed access to treatments** to stop progression to severe disease, easing the burden on health systems

# Therapeutics landscape | Progress on inpatient drugs, oral outpatient options on the horizon

## Existing products & efforts

### Inpatient care package

Focus on oxygen + corticosteroid treatment, adding recently recommended IL6 blockers, and potentially mAb cocktail (casirivimab/imdevimab)

- Over **\$97 million of oxygen provisions shipped** (to Jul '21)
- **\$417M million awarded to countries** for oxygen provisions through Global Fund C19RM

## Upcoming pipeline



### Outpatient Tx

Molnupiravir, fluvoxamine, and other therapies in clinical trials




### Inpatient Tx

Products with **better profile for LMICs** (e.g., baricitinib, empagliflozin)

# Therapeutics landscape | Timeline of upcoming actionable data

Limited success with repurposed therapeutics; potential interventions target key products

View as Sept 2021



1. Interim TOGETHER data 2. Final data from PRINCIPLE trial 3. Planned completion of COLCHICOVID trial 4. Estimated readout of ANTICOV data 5. Read-out date dependent on progress of RECOVERY trial patient recruitment over summer, additional recruitment now planned in India 6. Planned completion of Merck MOVE-OUT trial and Indian consortium trial; Interim data or Indian consortium trial unlikely to be sufficient to trigger guidelines, with DCGI unlikely to approve ahead of larger regulators 7. Planned completion date of MORNINGSKY trial 8. Estimated read-out of COMET-TAIL data - planned completion date of trial 2022 9. Final data from RECOVERY and REMAP-CAP 10. Read out of empagliflozin arm of RECOVERY expected in H2 2021

# ACT-A priorities for 2021-22: continuing to deploy, prepare & research

## *Deploy what we have*



### **Inpatients**

*(Severe & Critical cases)*

Drive uptake of the effective care package we already have



**Focus for today**

## *Prepare for what's coming*



### **Outpatients**

*(Mild & Moderate)*

Ensure access and country readiness for the promising products currently in Ph.3 trials



**Focus for today**

## *Enrich research pipeline*



### **R&D pipeline**

*(all use cases with outpatient emphasis)*


Enrich research pipeline, facilitate novel and combination treatment

# Deploy & prepare: priorities & challenges for the coming year



## Priorities for 2021-22

- Drive uptake of existing products for up to **6 million severe & critical patients**, including medical oxygen and drugs
- Enable access to new therapies for **mild & moderate cases**, including at-risk procurement for **up to 28 million high risk patients** to trigger procurement at scale



## Key challenges

- **Delayed clinical readouts**
- **Access challenges**, esp. biologics & novel products: limited supply, affordability, access terms, IP licenses esp. for small molecules
- Links between **diagnostics, treatments, and vaccine strategies**; need for test & care strategies